Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(50.0%)
Early Phase 1
1(50.0%)
2Total
Phase 2(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2)

Showing 2 of 2 trials
NCT06548139Phase 2Not Yet Recruiting

Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials

Role: collaborator

NCT05832073Early Phase 1Unknown

Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1

Role: collaborator

All 2 trials loaded